德琪医药－Ｂ招股说明书
– 5 –
1 (s)N D A FDA NDA 2020 2021 2
3 4 Origincell ATG-101 5
6 7 RAS RAF AML *
**
=
(i) (ii) NDA (iii) ATG-010 (selinexor) B NSCLC ATG-008 (onatasertib) HCC NSCLC 2019 B HCC NSCLC 68,200 137,600 369,400 761,000
1
***
ATG-010 (selinexor)
1 2.4 2
III BOSTON *IIb STORM *Ib/II STOMP **IIb SADAL ****
**
*** B
2018 5 23 II MARCH (NCT03944057)
2020 2021 NDA IND 2020 10 ATG-010 (selinexor) III 2021
II SEARCH (NCT03992339) 2021 NDA DLBCL 2020 Karyopharm ATG-010 (selinexor) R-GDP DLBCL